bluebird bio (bluebird bio) Forward Dividend Yield % : 0.00% (As of Apr. 27, 2024)

View and export this data going back to 2013. Start your Free Trial

What is bluebird bio Forward Dividend Yield %?

As of today (2024-04-27), the Forward Annual Dividend Yield of bluebird bio is 0.00%.

As of today (2024-04-27), the Trailing Annual Dividend Yield of bluebird bio is 0.00%.

BLUE's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.56
* Ranked among companies with meaningful Forward Dividend Yield % only.

bluebird bio's Dividends per Share for the three months ended in Sep. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of bluebird bio's Forward Dividend Yield %

For the Biotechnology subindustry, bluebird bio's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

bluebird bio's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, bluebird bio's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where bluebird bio's Forward Dividend Yield % falls into.

bluebird bio Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

bluebird bio (NAS:BLUE) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

bluebird bio Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of bluebird bio's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

bluebird bio (bluebird bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » bluebird bio Inc (NAS:BLUE) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

BLUE:Mexico

Address

455 Grand Union Boulevard, Somerville, MA, USA, 02145

Website

https://www.bluebirdbio.com

bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.

Executives

Richard A Colvin	officer: Chief Medical Officer	455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145
Andrew Obenshain	officer: President of SGD	C/O BLUEBIRD BIO, INC., 455 GRAND UNION BOULEVARD, SOMERVILLE MA 02145
Christopher Krawtschuk	officer: Chief Financial Officer	455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145
Thomas J Klima	officer: Chief Commercial Officer, SGD	C/O BLUEBIRD BIO, INC., 455 GRAND UNION BOULEVARD, SOMERVILLE MA 02145
Richard A. Paulson	director	85 WELLS AVENUE, NEWTON MA 02459
Nick Leschly	director, officer: President and CEO	C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Joseph Vittiglio	officer: Chief Business & Legal Officer	C/O BLUEBIRD BIO, INC., 455 GRAND UNION BLVD, SOMERVILLE MA 02145
Elisabeth Leiderman	director	1325 BOYLSTON STREET, SUITE 500, BOSTON MA 02215
Jason Cole	officer: SVP, Secy. & General Counsel	C/O BLUEBIRD BIO, INC, 455 GRAND UNION BOULEVARD, SOMERVILLE MA 02145
Anne-virginie Eggimann	officer: Chief Regulatory Officer	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Charlotte Jones-burton	director	455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145
Gina Consylman	officer: Chief Financial Officer	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Jessica Whitten	officer: Chief Accounting Officer	60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Sarah Js Glickman	director	60 BINNEY STREET, C/O BLUEBIRD BIO, INC., CAMBRIDGE MA 02142
Najoh Tita-reid	director	455 GRAND UNION BOULEVARD, C/O BLUEBIRD BIO, INC., SOMERVILLE MA 02145